Mayukh Sukhatme

Mayukh Sukhatme

President and Chief Investment OfficeratRoivant Sciences· In proxies 2021–2024

Pay in FY2024+43,735% from the year before · Roivant Sciences stock +42.8% the same year

Mayukh Sukhatme was paid $251.9M in FY2024 (Mar), up 43,735%. Roivant Sciences stock rose 42.8% that year.

Pay$100 in the stock at the end of FY22 → $213
Pay is from the Summary Compensation Table of each Roivant Sciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Roivant SciencesPublic company · 5 yr
    • President and Chief Investment Officer2021 – Present · 5 yrStock in role +356%

Roles come from the proxy statements of each company.

Boards1

  • Roivant SciencesDirector · 1 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?